These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38349858)

  • 1. Transcriptomic and network analysis identifies shared and unique pathways and immune changes across fibrotic interstitial lung diseases.
    Liu W; Huang K; Yang XZ; Wang P
    Aging (Albany NY); 2024 Feb; 16(4):3200-3230. PubMed ID: 38349858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.
    Marinescu DC; Hague CJ; Muller NL; Murphy D; Churg A; Wright JL; Al-Arnawoot A; Bilawich AM; Bourgouin P; Cox G; Durand C; Elliot T; Ellis J; Fisher JH; Fladeland D; Grant-Orser A; Goobie GC; Guenther Z; Haider E; Hambly N; Huynh J; Johannson KA; Karjala G; Khalil N; Kolb M; Leipsic J; Lok S; MacIsaac S; McInnis M; Manganas H; Marcoux V; Mayo J; Morisset J; Scallan C; Sedlic T; Shapera S; Sun K; Tan V; Wong AW; Zheng B; Ryerson CJ
    Chest; 2023 Dec; 164(6):1466-1475. PubMed ID: 37541339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological features of connective tissue disease-associated interstitial lung disease in transbronchial cryobiopsies.
    Churg A; Poletti V; Ravaglia C; Matej R; Vasakova MK; Hornychova H; Stewart B; Patel D; Duarte E; Gomez Manjarres DC; Mehta HJ; Vaszar LT; Tazelaar H; Wright JL
    Histopathology; 2025 Jan; 86(2):260-267. PubMed ID: 39223069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study.
    Zou M; Hu X; Song W; Gao H; Wu C; Zheng W; Cheng Z
    Clin Exp Med; 2023 Dec; 23(8):4809-4816. PubMed ID: 37864077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
    Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
    Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
    [No Abstract]   [Full Text] [Related]  

  • 7. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
    Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
    Front Immunol; 2021; 12():595811. PubMed ID: 33859634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Microenvironments and Disease Progression in Fibrotic Hypersensitivity Pneumonitis.
    De Sadeleer LJ; McDonough JE; Schupp JC; Yan X; Vanstapel A; Van Herck A; Everaerts S; Geudens V; Sacreas A; Goos T; Aelbrecht C; Nawrot TS; Martens DS; Schols D; Claes S; Verschakelen JA; Verbeken EK; Ackermann M; Decottignies A; Mahieu M; Hackett TL; Hogg JC; Vanaudenaerde BM; Verleden SE; Kaminski N; Wuyts WA
    Am J Respir Crit Care Med; 2022 Jan; 205(1):60-74. PubMed ID: 34724391
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study.
    Plantier L; Smolinska A; Fijten R; Flamant M; Dallinga J; Mercadier JJ; Pachen D; d'Ortho MP; van Schooten FJ; Crestani B; Boots AW
    Respir Res; 2022 Jan; 23(1):12. PubMed ID: 35057817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and management of cough in interstitial lung disease.
    Rasheed AZ; Metersky ML; Ghazal F
    Expert Rev Respir Med; 2023 Dec; 17(12):1177-1190. PubMed ID: 38159067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
    Wang S; Liu M; Li X; Zhang J; Wang F; Zhang C; Roden A; Ryu JH; Warrington KJ; Sun J; Matteson EL; Tschumperlin DJ; Vassallo R
    FASEB J; 2022 Jun; 36(6):e22336. PubMed ID: 35522243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease.
    Klay D; van der Vis JJ; Roothaan SM; Nguyen TQ; Grutters JC; Goldschmeding R; van Moorsel CHM
    Lung; 2021 Dec; 199(6):659-666. PubMed ID: 34812907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances with pharmacotherapy for the treatment of interstitial lung disease.
    Comes A; Sgalla G; Perrotta A; Richeldi L
    Expert Opin Pharmacother; 2022 Mar; 23(4):483-495. PubMed ID: 34907821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases.
    Stock CJW; Bray WG; Kouranos V; Jacob J; Kokosi M; George PM; Chua F; Wells AU; Sestini P; Renzoni EA
    Respirology; 2024 Mar; 29(3):228-234. PubMed ID: 37779266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular mechanism underlying dermatomyositis related interstitial lung disease: evidence from bioinformatic analysis and
    Zeng L; Tang Y; Zhang Y; Yue L; Ma G; Ye X; Yang L; Chen K; Zhou Q
    Front Immunol; 2023; 14():1288098. PubMed ID: 37928522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review.
    Enomoto N
    Respir Investig; 2024 May; 62(3):465-480. PubMed ID: 38564878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.
    Puiu R; Motoc NS; Lucaciu S; Ruta MV; Rajnoveanu RM; Todea DA; Man MA
    Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
    Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
    Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.